Clinical Trials
287 trialsTocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Masonic Cancer Center, University of Minnesota
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Groupe Francophone des Myelodysplasies
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Thomas Jefferson University
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Astellas Pharma Inc
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Stanford University
PTBCy
St. Petersburg State Pavlov Medical University
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Heinrich-Heine University, Duesseldorf
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Memorial Sloan Kettering Cancer Center
FluBuBe
St. Petersburg State Pavlov Medical University
UK-Haplo
University College, London
ICT-HCT
Fred Hutchinson Cancer Center
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
FLAT-Auto
IRCCS San Raffaele
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Masonic Cancer Center, University of Minnesota
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
Universitätsklinikum Hamburg-Eppendorf
SCT Plus Immune Therapy in Average Risk AML/MDS
New York Medical College
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Institutes of Health Clinical Center (CC)
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig